Fate Therapeutics reports Q3 2025 financial results, receives UK and EU trial authorization.

• Fate Therapeutics receives authorization to activate ex-US clinical trial sites for FT819 CAR T-cell product candidate • First systemic sclerosis patient treated in FT819 Phase 1 study with fludarabine-free conditioning • First patient treated with FT836, a MICA/B-targeted CAR T cell for solid tumors • Projected operating runway through 2027 with $226 million in cash and equivalents • Enables achievement of key clinical and collaboration milestones